Graeme J Hankey, neurologist at the Royal Perth Hospital and University of Western Australia, speaks on data from a sub-analysis of the ROCKET-AF study at the American Stroke Association’s International Stroke Conference 2012 which shows that rivaroxaban (Xarelto, Bayer Healthcare) might be better at preventing clot-related strokes in patients with atrial fibrillation while minimising the risk of causing a bleeding stroke.
Courtesy of the American Heart Association
